FDA approves J&J’s ICOTYDE for moderate-to-severe plaque psoriasis
CURRENT FULL VERSION: Johnson & Johnson has secured a notable new FDA win in immunodermatology, with the agency approving ICOTYDE (icotrokinra) on March 18, 2026 for moderate-to-severe plaque psoriasis in adults and in adolescents 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. J&J describes the medicine as an interleukin-23 receptor antagonist and a once-daily oral peptide, giving it a differentiated profile in a market where many of the most effective psoriasis therapies are injectable biologics. (investor.jnj.com)
The approval caps a fast-moving development program. J&J had disclosed in July 2025 that it submitted an NDA seeking the first U.S. approval for icotrokinra in plaque psoriasis, after presenting pivotal Phase 3 data from the ICONIC program. That program included ICONIC-LEAD, which enrolled adults and adolescents together, and ICONIC-ADVANCE 1 and 2, which compared the drug with placebo and with deucravacitinib, an established oral TYK2 inhibitor. The companies behind the asset are J&J and Protagonist Therapeutics, whose long-running collaboration produced icotrokinra from a peptide discovery platform. (investor.jnj.com)
On efficacy, J&J said the head-to-head superiority studies showed that about 70% of treated patients achieved IGA 0/1 and 55% achieved PASI 90 at Week 16. The company also said adverse reaction rates in ICOTYDE-treated patients were within 1.1% of placebo through Week 16, with no new safety signals identified through 52 weeks. Just days after the approval, J&J released one-year follow-up from ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD, emphasizing durability of skin clearance and a favorable long-term safety profile. (investor.jnj.com)
J&J and affiliated investigators are framing the approval as a meaningful shift in the treatment landscape because it combines an oral route with IL-23 pathway targeting, an approach more commonly associated with injectable biologics. In company materials, investigator Jennifer Soung, M.D. said the approval gives patients 12 and older access to a novel therapy capable of sustained skin clearance in a once-daily pill, while Linda Stein Gold, M.D. had previously highlighted the superiority data versus deucravacitinib as evidence that the drug could become an appealing option for patients seeking oral therapy. Those comments come from company-linked materials rather than independent editorial commentary, so they should be read as informed but promotional reactions. (jnj.com)
Why it matters: For veterinary professionals, this is a human drug approval, but it’s still worth watching as a signal from the broader inflammation and dermatology market. Companion animal medicine increasingly sits downstream of platform science, capital flows, and clinical validation established first in human health. A successful targeted oral peptide that can compete with established systemic therapies may reinforce industry confidence in oral immunology programs, including those aimed at chronic inflammatory disease. It also underscores how much strategic value large drugmakers continue to place on the IL-23 axis, which has become one of the most commercially and clinically important pathways in immune-mediated disease. (investor.jnj.com)
There’s also a competitive story here. J&J already has a strong psoriasis presence through TREMFYA, including a 2025 FDA pediatric plaque psoriasis approval, and icotrokinra broadens that franchise with an oral option that could be used earlier in the treatment journey. If uptake is strong, the approval may put more pressure on other oral psoriasis developers, including Takeda, which recently presented Phase 3 zasocitinib data at AAD 2026, according to PharmaShots. In Takeda’s LATITUDE PsO 3001 and PsO 3002 studies, conducted in 693 and 1,108 adults with moderate-to-severe plaque psoriasis, the company reported Week 16 superiority to both placebo and apremilast. In PsO 3001, 71.4% of patients on zasocitinib achieved sPGA 0/1, versus 10.7% on placebo and 32.1% on apremilast; 61.3% reached PASI 90 and 33.4% reached PASI 100. In PsO 3002, 69.2% achieved sPGA 0/1, versus 12.6% and 29.7%, while 51.9% reached PASI 90 and 25.2% reached PASI 100. Takeda also said responses improved through Week 24, included an early Week 4 PASI 75 signal in PsO 3002, and showed more than 90% durability at Week 60, with regulatory submissions planned starting in Takeda’s fiscal 2026. In other words, this isn’t just a single approval, it’s part of a larger contest over who defines the next generation of systemic psoriasis care. (investor.jnj.com)
What to watch: The next signals will be practical rather than scientific: publication of the final FDA label materials in Drugs@FDA, payer access and step-edit positioning, early prescribing trends versus biologics and TYK2 inhibitors, and pipeline expansion into ulcerative colitis and Crohn’s disease, where J&J has already advanced icotrokinra in additional studies. It will also be worth watching how quickly the oral psoriasis category becomes more crowded if Takeda follows through on planned submissions for zasocitinib after the LATITUDE program’s placebo- and apremilast-controlled results. (jnj.com)